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Rheumatoid Arthritis (RA) is the most common chronic inflammatory autoimmune disease involving joints. Among several
pathogenic mechanisms, the impairment of homeostatic regulators of inflammation seems to be critically important to
sustain persistent infiltration and activation of immune and stromal cells within the diseased synovium. Tyrosine kinase
receptors Tyro3, Axl, and Mer are members of the TAM family. Upon binding their ligands Growth Arrest-Specific gene 6
(Gas6) and Protein S (ProS1), TAM receptors (TAMs) exert numerous and diverse biologic functions. Activated Axl and
Mer, for instance, can negatively regulate the inflammatory cascade and mediate phagocytosis of apoptotic cells, contributing
to prevent the development of autoimmunity. Thus, a role for TAMs has been hypothesized in RA. In this review, we will
summarise unmet clinical needs in RA, depict the biology of TAMs and TAM ligands, focussing on their ability to regulate
the immune system and inflammation cascade, and finally offer an overview of the state-of-the-art literature about the
putative role of TAM axis in RA.
1. Introduction
Rheumatoid Arthritis (RA) is a chronic inflammatory auto-
immune disease characterised by persistent inflammation of
diarthrodial joints [1]. Despite significant advances in the
understanding andmanagement of RA, further studies evalu-
ating novel pathogenic pathways and therapeutic targets are
needed to improve the clinical outcome of patients. Among
several mechanisms, impairment of homeostatic regulators
of inflammation seems to be critically important to sustain
the persistent cellular infiltration and activation of immune
and stromal cells within the diseased synovium [2]. Tyro3,
Axl, and Mer are three tyrosine kinase receptor (TKR)
members of the TAM family, which can be activated by bind-
ing their cognate ligands Growth Arrest-Specific gene 6
(Gas6) and Protein S (ProS1) [3]. TAM receptors (TAMs)
have been implicated in several biological processes such
as inhibition of apoptosis and promotion of cell survival
and proliferation [4, 5], inhibition of granulocytes adhe-
sion to the endothelium [6], and stabilisation of blood
clots [7]. Furthermore, and of particular importance in the
context of RA, TAMs can also finely regulate the inflamma-
tory cascade [8] and mediate the engulfment of apoptotic
corpses [9], contributing to prevent the development of auto-
immune reactions.
Here, we will initially summarise unmet clinical needs in
RA (Section 2) and describe the biology of TAMs and TAM
ligands (Section 3). We will then focus on TAMs’ ability to
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control the immune system and inhibit the inflammatory
cascade (Section 4). Finally, we will offer an overview of the
state-of-the-art literature about the putative role of the
TAM axis in RA (Section 5).
2. Unmet Needs in Rheumatoid Arthritis
RA is the most common chronic inflammatory autoimmune
disease affecting joints. If not adequately treated, RA eventu-
ally causes long-term disabilities and poor quality of life [1].
RA pathogenesis is multifactorial and only partially under-
stood. In the prearticular phase of the disease, characterised
by systemic loss of the immune tolerance, autoantibodies
directed against arthritogenic peptides are generated in
genetically susceptible subjects [10]. Subsequently, multiple
factors such as viral infections, microvascular defects, and
local microtraumas likely contribute to shifting the patho-
genic process from the periphery to the joints, hence initiat-
ing the articular phase of the disease [2].
Within the affected joint, autoantibodies bind their
cognate antigens and activate the complement cascade,
ultimately triggering proinflammatory reactions mediated
by resident synovial cells and immune cells recruited from
peripheral blood. This persistent infiltration of the synovial
membrane by inflammatory cells is, at least partially, self-
sustained by intrinsic and/or acquired defects of homeostatic
regulatory mechanisms operating a negative feedback on the
inflammatory cascade [2, 11].
Over the last two decades, thanks to the introduction of
biologic agents into the therapeutic scenario, the clinical out-
come of RA patients has critically improved. Nevertheless,
substantial unmet clinical needs remain to be addressed for
further refining the diagnosis and ameliorating the prognosis
of patients. For instance, biomarkers able to accurately
predict the diagnosis, severity, and progression of RA have
yet to be defined. Moreover, a still significant percentage of
patients, despite being aggressively treated with multiple
agents, fail to reach a low-disease activity or remission status
[12]. In the era of precision medicine, the identification of
predictors able to guide the choice of the best drug for the
right patient represents one of the most important goals of
ongoing trials. Even if exciting news is currently coming
from the analysis of the cellular and molecular content of
the diseased synovial tissue [13], further investigations are
still required. To date, a few studies have explored TAMs’
pathogenic role and potential diagnostic and prognostic
value in RA. As described below, the biological features of
TAMs and TAM ligands make this system a promising can-
didate biomarker and a future therapeutic target in RA.
3. Biology of TAM Receptors and Ligands
3.1. Structure, Expression, and Activation of TAM Receptors
and Ligands. The acronym TAM is derived from the
names of the three RTK members of the family: Tyro3,
Axl, and Mer [14]. Structurally, all TAMs are considerably
similar and contain the following: an extracellular amino-
terminal region carrying tandem immunoglobulin-related
domains, which mediate ligands’ binding, followed by
two fibronectin type III repeats; a single-pass transmem-
brane domain; and a catalytically competent tyrosine
kinase intracellular domain [15, 16]. TAMs had been con-
sidered “orphan” receptors until 1995 when their ligands
ProS1 and Gas6 were identified [17]. Gas6 can bind and
activate all three TAMs, however, with different degrees
of affinity (Axl>Tyro3>>Mer); conversely, ProS1 is the
preferential ligand for Tyro3 and Mer but has a signifi-
cantly lower affinity for Axl [17, 18].
Although Axl, Mer, and Tyro3 mRNA can be detected in
embryonic tissues [19], TAMs are dispensable for embryonic
growth and nonessential for the viability of the foetus as
demonstrated by the healthy birth of triple TAM knockout
(KO) mice [20]. In adult tissues, TAMs are broadly expressed
but can be primarily found in the nervous and reproductive
systems, retinal cells, and hematopoietic lineages [21]. Mye-
loid cells (i.e., monocytes/macrophages and dendritic cells
(DCs)), in particular, display TAMs on their surface [8, 22]
though with distinctive features. On the one hand, Axl and
Tyro3 are usually upregulated by monocyte-derived DCs
[23] and, among them, Axl is preferentially induced by
GM-CSF and IFN-α stimulation [24]. On the other hand,
Mer is a typical macrophage receptor predominantly
expressed by anti-inflammatory macrophage M2c, obtained
in vitro by treating monocytes with M-CSF and IL-10 [25].
Overall, both Axl and Mer seem to be gradually acquired as
monocytes differentiate into DCs and macrophages, respec-
tively. Interestingly, despite being expressed by several
neoplastic lymphocytes, TAMs are almost undetectable in
nonpathologic B and T cells [21], except for specific subsets
of B cells [26] and CD4+CD25+ regulatory T cells [27].
Depending on which cells or tissues are expressed by,
TAMs can activate different intracellular pathways and medi-
ate a wide range of biological functions [28]. In most nonsen-
tinel cells, activation of TAM tyrosine kinases is coupled to the
downstream activation of the phosphoinositide-3-kinase
(PI3K)/AKT pathway. Conversely, in antigen-presenting
cells (APCs) and other immune cells harbouring the Type I
Interferon Receptor (IFNAR), the JAK/STAT signalling
becomes the preferential downstream pathway [29]. As
mentioned above, TAMs are activated upon binding their
cognate ligands Gas6 and ProS1. However, besides this
conventional ligand-dependent stimulation, in nonphysiolo-
gical circumstances of overexpression, Axl activation can also
occur without binding its ligand but through the aggregation
of extracellular domains and subsequent reciprocal auto-
phosphorylation [30].
3.2. Regulation of TAM Receptors: Shedding Mechanisms and
Epigenetic Modulation. Several mechanisms can critically
regulate TAM protein expression, including cleavage of
extracellular domains and epigenetic control of mRNA trans-
lation. Concerning the former, two A disintegrin and metal-
loproteinases (ADAM), namely ADAM10 and 17, are the
principal enzymes involved in the generation of soluble Axl
(sAxl) and soluble Mer (sMer) extracellular domains [31,
32]. TAMs shedding may have important physiological and
pathological implications: in fact, because of Axl high affinity
for its ligand Gas6, sAxl behaves as a potent decoy receptor
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for circulating Gas6. Hence, in the presence of excessive
cleavage, not only the amount of functional transmembrane
receptors is reduced but also the availability of Gas6 is
impaired as it is sequestered by sAxl [33]. Interestingly,
proinflammatory stimuli such as phorbol 12-myristate 13-
acetate (PMA) [31] and lipopolysaccharide (LPS) [32] are
inducers of Axl and Mer shedding, respectively. In this
context, the highly inflamed articular microenvironment
during RA might play an essential role by enhancing TAM
cleavage and, eventually, altering their homeostatic regula-
tion. Furthermore, it has been shown that rheumatoid
synovium expresses higher levels of both ADAM-10 and
ADAM-17 compared with osteoarthritic and healthy joints
[34]. Besides, RA-derived synovial fibroblasts further upreg-
ulate ADAMs’ expression upon stimulation with proinflam-
matory cytokines in comparison with resting cells [35].
Shedding of the ectodomain can unmask secondary cleavage
sites that, if activated, release soluble intracellular domains;
recently, it has been suggested that all three TAMs have intra-
membrane cleavage sites potentially targeted by gamma-
secretase shedding complexes [36].
Importantly, since soluble TAM ectodomains can be
easily quantified, they may become valuable diagnostic
and/or prognostic biomarkers in the context of inflam-
matory and autoimmune conditions. Indeed, significant
variations of plasmatic levels of TAMs and ligands have been
described in numerous pathological conditions. For
instance, raised concentrations of soluble TAMs associate
with lupus [37–39], Sjogren’s syndrome [40, 41], and RA
[42, 43]; Gas6 is heightened in a multitude of diseases, such
as inflammatory autoimmune demyelinating diseases [44],
Alzheimer’s disease [45], and hepatic fibrosis [46]. Higher
levels of Gas6 also predict oesophageal varices in patients
affected by hepatitis C virus (HCV) liver disease [47] and
correlate with disease severity in multiple sclerosis [48] and
renal involvement in systemic lupus erythematosus (SLE)
[49]. Conversely, other authors have found lower Gas6
plasmatic concentrations in lupus [50], Behcet’s disease
[51], and inflammatory bowel diseases [52] in comparison
with healthy controls. Heterogeneity of the cohorts included
in the studies might account for these discrepancies since
different ethnicity, stage of the disease, previous treatments,
and comorbidities can influence the level of expression of
both soluble TAMs and TAM ligands.
Epigenetic control, which is acquiring increasing
importance, is another mechanism able to regulate TAM
protein expression. Briefly, miRs are small noncoding
RNA that can modulate the mRNA translation of target
genes, hence altering their effector pathways. Research of
Axl-modulating miRs was initially performed in malignant
cells and tissues and provided a fascinating list of candidates
[53]: among them,miR-34a has been selected and studied also
in the context of inflammation. Interestingly, it was found that
the inhibition of miR-34a in macrophages caused the down-
regulation of proinflammatory cytokines’ release [54] and,
in line with these results, that RA DCs were characterised by
unrestrained activation of miR-34a driving the uncontrolled
production of inflammatory molecules secondary to Axl
repression [55].
4. TAM Receptors as Regulators of the
Immune System
TAMs’ ability to maintain immune system homeostasis and
control inflammatory responses in adult tissues was firstly
suggested by the phenotype of Mer kinase-dead (MerKD)
mice, characterised by an excessive production of Tumor
Necrosis Factor (TNF) α upon LPS stimulation and death
by endotoxic shock caused by less-lethal doses of LPS [56].
Later on, it was also shown that mutants lacking all three
TAMs (known as TAM-/- mice) developed multiorgan signs
and symptoms typical of autoimmune inflammatory diseases
[20, 21]. TAM-/- mice became progressively blind and sterile
and showed gradual enlargement of secondary lymphoid
organs caused by an uncontrolled proliferation of B/T
lymphocytes [21]; at about six months of age, they displayed
a wide range of full-blown clinical, serological, and histolog-
ical manifestations including immunoglobulin deposits in
glomeruli, circulating autoantibodies, vasculitic skin lesions,
alopecia, and swollen joints [20, 21].
In the attempt to explain these broad pathological
manifestations, two essential TAM-regulated functions were
identified and described: the inhibition of Toll-Like-
Receptors (TLRs) induced inflammatory cascade and the
uptake of apoptotic cells by APCs. The impairment of these
mechanisms in the absence of TAMs could, at least partially,
recapitulate and explain TAM-/- phenotype.
4.1. Inhibition of Toll-Like Receptor- (TLR-) Mediated
Inflammation. Upon being bound by their ligands, TLRs
respond by enhancing the release of proinflammatory cyto-
kines, which are crucial for host defence mechanisms against
microbial pathogens. On the other hand, failure of TLR fine-
tuning causing their unrestrained activation may generate an
inflamed environment promoting autoimmunity [57]. APCs
like DCs and macrophages use TAMs to regulate and switch
off inflammatory reactions secondary to TLR stimulation,
thus preventing the chronic activation of TAM-expressing
cells [22].
Molecular mechanisms by which TAMs exert this inhib-
itory function have been particularly well studied in DCs
expressing Axl. The initial inflammatory rush provoked by
TLR activation and typically exploiting the IFNAR/STAT1
as downstream activator signal can, in turn, also prompt
Axl upregulation. Once Axl has been exposed on the cell
membrane and activated by its ligand, it can complex with
the IFNAR and usurp the IFNAR/STAT1 machinery from
TLRs, eventually determining the switch from a pro- to an
anti-inflammatory phenotype of the cell. Coupling of Axl
with IFNAR upregulates the transcription of inhibitory
factors, for instance, the suppressors of cytokine signalling
family 1/3 (SOCS1/3) [22]. Mer is likewise important for
the inhibition of inflammation in macrophages [58] and
macrophage-like cell lines [8]. As reported by Alciato et al.,
Mer activation by its ligand Gas6 drives the downregulation
of LPS-induced production of TNF-α and IL-6 in monocyte-
derived macrophages and U937-derived macrophage-like
cells by triggering PI3K/AKT and NF-kappa B pathways [8].
Furthermore, as suggested by Zizzo et al., the Mer/Gas6 axis
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not only can prevent proinflammatory cytokines’ release but
also induce the expression of anti-inflammatory mediators
(i.e., IL-10) by M2c anti-inflammatory macrophages. Ulti-
mately, Mer/Gas6-induced IL-10 represents a positive feed-
back loop for M2c cell homeostasis, and it is critical for
maintaining an anti-inflammatory and immune-tolerant
environment [25]. TAMs’ ability to contain the overproduc-
tion of TNFα and IL-6 is particularly important in the context
of RA since both of these cytokines are abundantly produced
within the rheumatoid synovial tissue and sustain the chronic
inflammatory process [59, 60]. Clinical efficacy of biologic
agents targeting TNFα and IL-6 (e.g., infliximab [61] and
tocilizumab [62], respectively) further confirms the detrimen-
tal effects played by these molecules in RA.
4.2. Phagocytosis of Apoptotic Cells. The second TAM-
mediated mechanism relevant to the immune system re-
gulation is the phagocytosis of apoptotic cells, also called
efferocytosis. Removal of apoptotic debris is crucial for
maintaining adult tissues healthy and functional. In mice
lacking TAMs, initial evidence of defective efferocytosis
can be observed in tissues and organs characterised by
high cellular turnover, for instance, retina, reproductive,
and immune system. Failure to phagocyte apoptotic resi-
dues in these tissues clinically manifests with blindness,
sterility, and pathological enlargement of secondary lym-
phoid organs, respectively [20]. Unremoved apoptotic cells
are a source of autoantigens and can drive the deve-
lopment of autoimmunity [63, 64], thus underpinning a
strong link between the absence of TAMs and the broad-
spectrum autoimmune manifestations observed in the
triple KO.
The mechanism of efferocytosis used by TAMs is peculiar
and carefully regulated. During apoptosis, dying cells expose
phosphatidylserine (PtDSer) on their membrane as an “eat
me” signal, which makes phagocytes able to discriminate
them from other necrotic or healthy cells. TAM ligands
Gas6 and Pros1 allow TAM-mediated efferocytosis by
binding the PtDSer residues on apoptotic cells via their Gla
domains and TAMs on APCs via their amino-terminal
region. In this way, TAM ligands function as a “bridge”
between apoptotic cells and TAM-expressing phagocytes
[65]. Mer was the first TAM receptor discovered to mediate
efferocytosis thanks to early experiments performed using
MerKD mice. MerKD-derived macrophages were indeed
unable to adequately clear thymocytes, but fascinatingly,
their phagocytosis deficiency was restricted to apoptotic cells
and independent of Fc receptor. Altogether, these findings
suggested a critical and exclusive role of Mer in the clearance
of apoptotic bodies [66].
Even though Mer has been historically considered the
only TAM responsible for the efferocytosis process, recent
data highlighted that, under certain circumstances, also other
members of the TAM family can acquire phagocytic activity
[33]. Depending on the surrounding microenvironment, the
same cell type can upregulate either Mer or Axl: in the pres-
ence of tolerogenic or immunosuppressive stimuli, Mer is the
principal mediator of efferocytosis, and its final aim is main-
taining normal tissue cellularity in physiological conditions
or upon anti-inflammatory treatment; conversely, following
proinflammatory activation of phagocytes, Mer is downregu-
lated and, in turn, Axl takes control of the process [33]. Nota-
bly, in RA synovial tissue, NF-κB is strongly activated and
provides a robust prosurvival signal and sustains the resis-
tance to apoptosis [67]. Thus, once again, a strong link
between one of TAM-mediated functions and the develop-
ment of RA exists, suggesting that TAMs may be involved
in the pathogenesis of the disease.
4.3. TAM Receptors Link the Innate and Adaptive Immunity.
Once activated, cells of the adaptive immune system should
feedback to innate immune cells to avoid their chronic and
uncontrolled activation. Due to their characteristics, includ-
ing the relatively late appearance in evolution, TAMs seem
designated to represent this important connection.
In favour of this hypothesis, it has been recently showed
that TAM ligand ProS1 is upregulated exclusively by acti-
vated (not resting) T cells and can inhibit their proliferation
[68]. The mechanism proposed for explaining this process
involves ProS1 ability to create a bridge between PtDSer,
exposed by T cells only transitorily after being activated,
and TAMs expressed by APCs [69]. ProS1, by binding
PtDSer on T cells with its Gla domain and TAMs harboured
by DCs with its SHBG domain, favours the connection
between these two cell types from the adaptive and innate
immune systems. The interaction between TAM/PtDSer
drives an inhibitory signal that restrains the proinflammatory
activation of DCs, hence limiting the production of cytokines
such as IL-6 and TNFα, and will also ultimately inhibit T
cells. As a proof of concept, preventing ProS1 to bind acti-
vated T cells triggered a rapid increase of activated DCs and
proinflammatory molecule release [68].
Virtually, all TAM activities listed so far occur because of
their expression by innate immune cells (either monocytes/-
macrophages or DCs). However, as an exception, a new TAM
function involving CD4+CD25+ T regulatory (T-reg) cells
has recently been described. T-reg cells exert their regulatory
role largely by preventing the immune cell-induced organ
damage. On the one hand, by suppressing autoreactive
lymphocytes, T-reg cells are fundamental to avoid autoim-
munity; on the other hand, however, an excessive activation
of T-reg cells would lead to unhealthy immunosuppression.
Defective expression, functionality, and generation of T-reg
cells have been described in several autoimmune conditions
including RA, in which they are highly present within the
inflamed synovial tissue but reduced in the periphery [70].
Surprisingly, Axl and Mer have been detected on the surface
of T-reg cells; once activated, Axl/Gas6 enhances the
suppressive capacity of T-reg, supporting, once again, Gas6
anti-inflammatory abilities [27].
Overall, the interaction between TAMs, Gas6/ProS1 and
innate/adaptive cells is a complex and finely-tuned process.
Small changes to this delicate balance could favour the devel-
opment of autoimmunity and chronic inflammation. Little is
known at this regard in RA, but compelling evidence is grow-
ing, and future studies will hopefully further elucidate these
critical aspects.
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5. TAM Receptors Implications in
Rheumatoid Arthritis
As mentioned above, the relevance of TAMs in the develop-
ment and progression of inflammatory arthritis was initially
hinted by the phenotype of TAM-/- mice, characterised by
broad-spectrum autoimmunemanifestations, predominantly
resembling SLE but also including inflammatory arthritis
[21]. So far, human studies mainly focussed on TAMs’ role
in SLE showing that impairment in this receptor system is
associated with lupus development, and soluble TAMs/li-
gands may be valuable diagnostic and/or prognostic bio-
markers in this condition [3, 71]. Additional and new
evidence about TAMs in RA has recently become available
and is continuously growing. Over the last decades, several
studies have investigated different models of arthritis in
TAM single, double, and triple KO mice. One of the most
accredited hypotheses that researchers are trying to prove
implicates that dysregulation of the TAM axis triggers auto-
immune reactions and the development of chronic inflam-
mation within the synovial tissue. If this is correct,
adjustments of the “aberrant” TAM system could represent
a promising therapeutic target in arthritis.
Following the initial report of the triple TAM KO pheno-
type, a recent work on the same mice quite surprisingly
showed that, in comparison with wild types (WT), KO litter-
mates had neither macroscopic nor histological evidence of
inflammatory arthritis in ankle joints until the age of 52
weeks [72]. As suggested by the authors, a different pheno-
type observed in a genotypically identical animal model
may be justified by changes in the interplay between genetic
and environmental factors, including, for example, improved
cleanliness of facilities and modifications of the microbiota.
The latter, in particular, could represent an exciting link with
RA as the dysbiosis seems to be a promoter of inflammatory
arthritis [73]. Despite not showing clinically evident arthritis,
however, both adolescent and adult TAM-/- mice had signif-
icantly more marked bone marrow oedema, which is an early
sign of arthritis [72].
Further studies from the same group also showed that in
a KRN serum transfer model of arthritis, the absence of Axl
(Axl-/-) or Mer (Mer-/-) caused more severe disease in
comparison with WT [74, 75]. Of note, the exacerbated
pathology was observed only in ankles of Axl-/- mice, whereas
no effect was seen in the knees of Axl KO mice [75]. The
histological analysis of the synovial tissue enabled a potential
interpretation for this clinical outcome. While ankle syno-
vium was characterised by high expression of Axl and a
predominance of anti-inflammatory M2 macrophages,
synovial tissue sampled from the knees had scant M2 macro-
phages and virtually absent Axl. Mer-deficient mice had
instead aggravated disease in all the joints assessed [75].
The first in vivo evidence that TAMs might be therapeu-
tically exploited to improve arthritis was provided in CIA
mice treated with adenoviruses overexpressing ProS1 or
Gas6. Intra-articular delivery of both TAM ligands Gas6
and ProS1 caused clinical and histological improvement by
decreasing the production and release of Th1- and Th17-
related proinflammatory cytokines (e.g., IL12/IFNγ and IL-
23/IL-17, respectively) [76]. In contrast, only ProS1-
overexpressing virus administered via a systemic route was
able to improve the disease and reduce the number of splenic
Th1-cells, leaving Th17 levels unaffected [76]. TAM ligands’
effects may, therefore, depend on the delivery route and be
“broader” when given locally. In line with these findings, it
has been reported that the cytokine profile of in vitro stimu-
lated peripheral blood CD4+ T cells isolated from Axl-/-/Mer-
/- mice is characterised by higher IFNγ but normal IL-17 [77].
The protective role played by Mer activation by its ligand
ProS1 has been lately further confirmed in a KRN serum
transfer arthritis model [74] and in a three-dimensional
model of human synovium [74], hence enhancing the trans-
lational value of this discovery. On the other hand, Mer
agonist antibodies were shown to have instead a detrimental
effect on arthritis, which can be explained by their capacity of
inhibiting Mer-mediated efferocytosis, proving that apopto-
tic cells removal is fundamental for homeostasis of the
synovial tissue.
More recently, Culemann et al. found that Axl is
expressed by a distinct subset of CX3CR1+ tissue-resident
macrophages forming an immunological barrier at the
synovial lining. These peculiar macrophages do not derive
from circulating monocytes, proliferate locally, and share
features with epithelial cells. By creating tight junctions and
expressing anti-inflammatory receptors, these lining-layer
macrophages tend to isolate the synovium and prevent the
infiltration of inflammatory cells [78].
In contrast with the protective role hypothesised for Axl
and Mer, induction of arthritis in Tyro3-/- mice revealed that
the third member of TAMs might instead play a proarthritic
role. In particular, Tyro3 KO mice had less marked synovial
fibroblast proliferation and osteoclast activation and were
protected from bone damage in comparison with WT
controls [79]. Furthermore, circulating levels of soluble
Tyro3 positively correlated with disease activity and erosive
burden in patients with RA [80]. It seems, therefore, that acti-
vated Tyro3 may be responsible for stimulating synovial
hypertrophy, cartilage destruction, and bone erosion,
suggesting a dual antithetic role for the TAM axis in arthritis
depending on which receptor is activated, i.e., an anti-
inflammatory effect in case of Axl or Mer but proerosive if
Tyro3 is triggered. Of course, these observations should be
taken into account when hypothesising a therapeutic exploi-
tation of TAMs in inflammatory arthritis.
In contrast with a rather high number of studies in
animal models, investigations of the TAM system in
patients with RA have only recently returned a hot topic
of research after an opening report published in 1999
when O’Donnel et al. found that Axl was expressed by a
discrete subset of synoviocytes and vascular smooth
muscle cells [43]. Our preliminary unpublished data have
confirmed that Axl seems preferentially expressed by a
subset of synovial lining macrophages, suggesting that it
might play a similar “barrier” role as described in animal
models of experimental arthritis.
It has been hypothesized that impaired TAM functioning
prevents synovial cells to properly switch the inflammatory
reactions off, thus triggering the development of chronic
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arthritis. The assumption of a defective expression of Axl in
patients with RA was elegantly demonstrated in 2017 by
Kurowska-Stolarska et al., who showed that CD1c+ DCs
isolated from patients with RA have constitutively high levels
of miR-34a and, subsequently, inhibited Axl expression in
comparison with healthy donors [55]. Importantly, by
inhibiting miR-34a, mice become resistant to arthritis, and
DCs acquire back the ability to limit proinflammatory cyto-
kine production.
As mentioned above, the Mer/Gas6 axis mediates anti-
inflammatory effects in CD206+ CD163+ M2c macrophages
by reducing the release of proinflammatory molecules like
TNF or IL-6 [8] and, at the same time, by inducing anti-
inflammatory mediators such as IL-10, which, in turn, can
also positively regulate Gas6 continued secretion [25]. Inter-
estingly, monocyte-derived macrophages isolated from RA
patients treated with TNF-inhibitors showed downregulation
of surface markers typically associated with inflammation
(e.g., CD40 and CD80) but also upregulation of Mer, hence
suggesting that, upon treatment, cells acquire the same
anti-inflammatory properties as other Mer-positive macro-
phages. In line with this, in vitro studies confirmed that
anti-TNF agents were able to inhibit proinflammatory cyto-
kines and upregulate IL-10, activating a positive feedback
mechanism involving the Gas6/Mer axis that, ultimately,
limited the inflammatory cascade [81].
Recently, single-cell transcriptomic profiling of synovial
tissue allowed the identification of several distinct subsets of
synovial macrophages, differently expressed based on the
nature and stage of the disease. In keeping with its postulated
anti-inflammatory role, Mer was significantly highly
expressed in osteoarthritic tissue compared to RA; moreover,
among RA-specific macrophage subsets, Mer was upregu-
lated in the so-called “anti-inflammatory” group [82]. Not
surprisingly, therefore, emerging data suggest that synovial
macrophages isolated fromRApatients in remission are char-
acterised by a CD163/CD206/Mer-positive signature [83].
The critical regulatory role played by TAM shedding and
soluble TAM generation has gathered growing evidence. As
mentioned above, indeed, quantification of circulating solu-
ble TAMs and TAM ligands may represent a novel interest-
ing biomarker system. For instance, in RA, sTyro3 serum
levels were found elevated compared to healthy controls
and correlated with rheumatoid factor titre, the number of
swollen joints, and joint erosion scores [80]. The role and
interpretation of sMer plasma levels, instead, are still contro-
versial. In one of the available reports, sMer was significantly
lower in comparison with healthy controls, with no correla-
tion observed between sMer and disease activity scores;
conversely, a different study reported increased levels of
circulating sMer in RA, however, reiterating the absence of
significant correlations with clinical parameters [84].
Lower levels of Gas6, ProS1, and sAxl in RA have also
been documented [42, 43]. Gas6 and sAxl, both significantly
decreased in patients compared to healthy controls,
positively correlated between them; Gas6 also negatively
correlated with the presence of erosions and positively with
disease activity scores [42]. Because in RA several disease
processes occur at the joint site, the discovery that sAxl is
one of the most abundant proteins detected in synovial fluid
of RA patients suggests that dysregulation of Axl synovial
expression may be a pathogenic pathway worth to be
explored in future studies [85].
6. Conclusion
RA is a chronic inflammatory autoimmune disease affecting
joints. Impairment of homeostatic regulators of inflammation
likely contributes to the development of persistent inflamma-
tory infiltration of the diseased synovium. Because the defec-
tive functionality of TKRs Tyro3, Axl, and Mer (TAM)
results in the abnormal activation of the immune system, it
has been postulated that these receptors may be implicated
in the development of autoimmune diseases including RA.
A protective role for Axl and Mer is supported by finding
that induced arthritis is significantlymore severe inmice lack-
ing these two receptors. Moreover, Axl likely contributes to
physically protecting the joint as it has been found expressed
by a special subset of CX3CR1+ lining macrophages originat-
ing from synovial precursors and able to form a tight
function-mediated barrier. Interestingly, RA-derived DCs
have defective Axl expression secondary to the upregulation
of its inhibitory micro-RNAmiR-34a. Mer, which is typically
expressed by anti-inflammatoryM2c-polarisedmacrophages,
is upregulated in noninflammatory arthritis like osteoarthritis
and RA in remission. Plausibly, Mer plays a crucial role in the
synovium by enhancing IL-10, inhibiting proinflammatory
cytokines production, and preventing the accumulation of
apoptotic cells. In contrast with these results, data about the
role of Tyro3 in arthritis showed that its activation is detri-
mental for the joints as it mediates synovial hypertrophy


























Figure 1: Model of TAM receptors and ligands’ effects in synovial
tissue. Axl and Mer, once activated by their cognate ligands, exert a
protective role within the joint by reducing the production of
proinflammatory cytokines, such as TNF and IL-6, and triggering
the phagocytosis of apoptotic cells. Axl, specifically, also contributes
to form a barrier on the synovial lining while Mer further enhances
the anti-inflammatory response by upregulating IL-10. Axl is
negatively regulated by miR-34a, which is constitutively activated in
RA DCs, and can be cleaved and released as soluble (s) Axl in the
joint space by proteinases like ADAM10/17. In contrast, Tyro3 may
foster synovial hypertrophy of fibroblast-like-synoviocytes (FLS)
and increase bone loss.
6 Disease Markers
exogenous administration of TAM ligands seems to amelio-
rate the disease in experimental models of arthritis. Finally,
there is growing attention to the quantification of soluble cir-
culating TAMreceptors/ligands and its relationshipwith clin-
ical phenotypes and disease progression.
In conclusion, available evidence suggests that Axl, Mer,
and Tyro3 might play an important and multifaceted role
in RA (Figure 1), and further studies on this topic are called
to clarify TAMs’ role and therapeutic potential.
Conflicts of Interest
The authors declare no conflicts of interests.
References
[1] D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid
arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010.
[2] G. S. Firestein and I. B. Mcinnes, “Immunopathogenesis of
rheumatoid arthritis,” Immunity, vol. 46, no. 2, pp. 183–196,
2017.
[3] C. V. Rothlin and G. Lemke, “TAM receptor signaling and
autoimmune disease,” Current Opinion in Immunology,
vol. 22, no. 6, pp. 740–746, 2010.
[4] S. Goruppi, E. Ruaro, and C. Schneider, “Gas6, the ligand of
Axl tyrosine kinase receptor, has mitogenic and survival
activities for serum starved NIH3T3 fibroblasts,” Oncogene,
vol. 12, no. 3, pp. 471–480, 1996.
[5] P. P. Sainaghi, L. Castello, L. Bergamasco, M. Galletti,
P. Bellosta, and G. C. Avanzi, “Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor,”
Journal of Cellular Physiology, vol. 204, no. 1, pp. 36–44, 2005.
[6] G. C. Avanzi, M. Gallicchio, F. Bottarel et al., “GAS6 inhibits
granulocyte adhesion to endothelial cells,” Blood, vol. 91,
no. 7, pp. 2334–2340, 1998.
[7] A. Angelillo-Scherrer, L. Burnier, N. Flores et al., “Role of Gas6
receptors in platelet signaling during thrombus stabilization
and implications for antithrombotic therapy,” The Journal of
Clinical Investigation, vol. 115, no. 2, pp. 237–246, 2005.
[8] F. Alciato, P. P. Sainaghi, D. Sola, L. Castello, and G. C. Avanzi,
“TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in
monocytes/macrophages,” Journal of Leukocyte Biology.,
vol. 87, no. 5, pp. 869–875, 2010.
[9] H. A. Anderson, C. A. Maylock, J. A. Williams, C. P. Paweletz,
H. Shu, and E. Shacter, “Serum-derived protein S binds to
phosphatidylserine and stimulates the phagocytosis of apopto-
tic cells,” Nature Immunology, vol. 4, no. 1, pp. 87–91, 2003.
[10] I. B. Mcinnes and G. Schett, “The pathogenesis of rheumatoid
arthritis,” The New England Journal of Medicine, vol. 365,
no. 23, pp. 2205–2219, 2011.
[11] E. M. Tan and J. S. Smolen, “Historical observations contribut-
ing insights on etiopathogenesis of rheumatoid arthritis and
role of rheumatoid factor,” The Journal of Experimental Med-
icine, vol. 213, no. 10, pp. 1937–1950, 2016.
[12] E. Astorri, A. Nerviani, M. Bombardieri, and C. Pitzalis,
“Towards a stratified targeted approach with biologic treat-
ments in rheumatoid arthritis: role of synovial pathobiology,”
Current Pharmaceutical Design, vol. 21, no. 17, pp. 2216–
2224, 2015.
[13] F. Humby, M. Lewis, N. Ramamoorthi et al., “Synovial cellular
and molecular signatures stratify clinical response to
csDMARD therapy and predict radiographic progression in
early rheumatoid arthritis patients,” Annals of the Rheumatic
Diseases, vol. 78, pp. 761–772, 2019.
[14] D. Prasad, C. V. Rothlin, P. Burrola et al., “TAM receptor
function in the retinal pigment epithelium,” Molecular and
Cellular Neurosciences, vol. 33, no. 1, pp. 96–108, 2006.
[15] X. Huang, P. Finerty, J. R. Walker et al., “Structural insights
into the inhibited states of the Mer receptor tyrosine kinase,”
Journal of Structural Biology, vol. 165, no. 2, pp. 88–96, 2009.
[16] C. Heiring, B. Dahlbäck, and Y. A. Muller, “Ligand recognition
and homophilic interactions in Tyro3: structural insights into
the Axl/Tyro3 receptor tyrosine kinase family,” Journal of Bio-
logical Chemistry, vol. 279, no. 8, pp. 6952–6958, 2004.
[17] T. N. Stitt, G. Conn, M. Gore et al., “The anticoagulation factor
protein S and its relative, Gas6, are ligands for the Tyro 3/Axl
family of receptor tyrosine kinases,” Cell, vol. 80, no. 4,
pp. 661–670, 1995.
[18] K. Ohashi, K. Nagata, J. Toshima et al., “Stimulation of sky
receptor tyrosine kinase by the product of growth arrest-
specific gene 6,” Journal of Biological Chemistry, vol. 270,
no. 39, pp. 22681–22684, 1995.
[19] C. Lai and G. Lemke, “An extended family of protein-tyrosine
kinase genes differentially expressed in the vertebrate nervous
system,” Neuron, vol. 6, no. 5, pp. 691–704, 1991.
[20] Q. Lu, M. Gore, Q. Zhang et al., “Tyro-3 family receptors are
essential regulators of mammalian spermatogenesis,” Nature,
vol. 398, no. 6729, pp. 723–728, 1999.
[21] Q. Lu and G. Lemke, “Homeostatic regulation of the immune
system by receptor tyrosine kinases of the Tyro 3 family,”
Science, vol. 293, no. 5528, pp. 306–311, 2001.
[22] C. V. Rothlin, S. Ghosh, E. I. Zuniga, M. B. A. Oldstone, and
G. Lemke, “TAM receptors are pleiotropic inhibitors of the
innate immune response,” Cell, vol. 131, no. 6, pp. 1124–
1136, 2007.
[23] H. M. Seitz, T. D. Camenisch, G. Lemke, H. S. Earp, and G. K.
Matsushima, “Macrophages and dendritic cells use different
Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells,”
The Journal of Immunology, vol. 178, no. 9, pp. 5635–5642,
2007.
[24] S. Scutera, T. Fraone, T. Musso et al., “Survival and migration
of human dendritic cells are regulated by an IFN-α-inducible
Axl/Gas6 pathway,” Journal of Immunology, vol. 183, no. 5,
pp. 3004–3013, 2009.
[25] G. Zizzo, B. A. Hilliard, M. Monestier, and P. L. Cohen,
“Efficient clearance of early apoptotic cells by human macro-
phages requires M2c polarization and MerTK induction,”
Journal of Immunology, vol. 189, no. 7, pp. 3508–3520, 2012.
[26] W.-H. Shao, R. A. Eisenberg, and P. L. Cohen, “TheMer recep-
tor tyrosine kinase is required for the loss of B cell tolerance in
the chronic graft-versus-host disease model of systemic lupus
erythematosus,” The Journal of Immunology, vol. 180, no. 11,
pp. 7728–7735, 2008.
[27] G.-J. Zhao, J.-Y. Zheng, J.-L. Bian et al., “Growth Arrest-
Specific 6 Enhances the Suppressive Function of CD4+CD25+
Regulatory T Cells Mainly through Axl Receptor,” Mediators
of Inflammation, vol. 2017, Article ID 6848430, 13 pages,
2017.
[28] M. Schoumacher and M. Burbridge, “Key roles of AXL and
MER receptor tyrosine kinases in resistance to multiple anti-
cancer therapies,” Current Oncology Reports, vol. 19, no. 3,
p. 19, 2017.
7Disease Markers
[29] G. Lemke and C. V. Rothlin, “Immunobiology of the TAM
receptors,” Nature Reviews Immunology, vol. 8, no. 5,
pp. 327–336, 2008.
[30] P. Bellosta, M. Costa, D. A. Lin, and C. Basilico, “The receptor
tyrosine kinase ARK mediates cell aggregation by homophilic
binding,” Molecular and Cellular Biology, vol. 15, no. 2,
pp. 614–625, 1995.
[31] J. P. O'Bryan, Y.W. Fridell, R. Koski, B. Varnum, and E. T. Liu,
“The transforming receptor tyrosine kinase, Axl, is post-
translationally regulated by proteolytic cleavage,” Journal of
Biological Chemistry, vol. 270, no. 2, pp. 551–557, 1995.
[32] E. Thorp, T. Vaisar, M. Subramanian, L. Mautner, C. Blobel,
and I. Tabas, “Shedding of the Mer tyrosine kinase receptor
is mediated by ADAM17 protein through a pathway involving
reactive oxygen species, protein kinase Cδ, and p38 mitogen-
activated protein kinase (MAPK),” Journal of Biological Chem-
istry, vol. 286, no. 38, pp. 33335–33344, 2011.
[33] A. Zagórska, P. G. Través, E. D. Lew, I. Dransfield, and
G. Lemke, “Diversification of TAM receptor tyrosine kinase
function,” Nature Immunology, vol. 15, no. 10, pp. 920–928,
2014.
[34] T. Isozaki, B. J. Rabquer, J. H. Ruth, G. K. Haines, and A. E.
Koch, “ADAM-10 is overexpressed in rheumatoid arthritis
synovial tissue and mediates angiogenesis,” Arthritis & Rheu-
matology, vol. 65, no. 1, pp. 98–108, 2013.
[35] S. Ishii, T. Isozaki, H. Furuya et al., “ADAM-17 is expressed on
rheumatoid arthritis fibroblast-like synoviocytes and regulates
proinflammatory mediator expression and monocyte adhe-
sion,” Arthritis Research & Therapy, vol. 20, no. 1, article
159, 2018.
[36] J. A. M. Merilahti, V. K. Ojala, A. M. Knittle, A. T. Pulliainen,
and K. Elenius, “Genome-wide screen of gamma-secretase-
mediated intramembrane cleavage of receptor tyrosine
kinases,” Molecular Biology of the Cell, vol. 28, no. 22,
pp. 3123–3131, 2017.
[37] J. J. Orme, Y. Du, K. Vanarsa, J. Mayeux, and L. Li, “Height-
ened cleavage of Axl receptor tyrosine kinase by ADAMmetal-
loproteases may contribute to disease pathogenesis in SLE,”
Clinical Immunology, vol. 169, pp. 58–68, 2016.
[38] G. Zizzo, J. Guerrieri, L. M. Dittman, J. T. Merrill, and P. L.
Cohen, “Circulating levels of soluble MER in lupus reflect
M2c activation of monocytes/macrophages, autoantibody
specificities and disease activity,” Arthritis Research & Ther-
apy, vol. 15, no. 6, p. R212, 2013.
[39] H. Zhu, X. Sun, L. Zhu et al., “The expression and clinical
significance of different forms of Mer receptor tyrosine kinase
in systemic lupus erythematosus,” Journal of Immunology
Research, vol. 2014, Article ID 431896, 12 pages, 2014.
[40] B. Qin, J. Wang, N. Ma et al., “The association of Tyro3/Axl/-
Mer signaling with inflammatory response, disease activity in
patients with primary Sjogren's syndrome,” Joint, Bone, Spine,
vol. 82, no. 4, pp. 258–263, 2015.
[41] C.-H. Chen, H.-C. Chen, C.-C. Chang et al., “Growth arrest-
specific 6 protein in patients with Sjögren syndrome: determi-
nation of the plasma level and expression in the labial salivary
gland,” PLoS One, vol. 10, no. 10, article e0139955, 2015.
[42] I. H. Bassyouni, M. M. El-Wakd, N. A. Azab, and R. H.
Bassyouni, “Diminished soluble levels of growth arrest
specific protein 6 and tyrosine kinase receptor Axl in
patients with rheumatoid arthritis,” International Journal
of Rheumatic Diseases, vol. 20, no. 1, pp. 53–59, 2017.
[43] K. O'Donnell, I. C. Harkes, L. Dougherty, and I. P. Wicks,
“Expression of receptor tyrosine kinase Axl and its ligand
Gas6 in rheumatoid arthritis: evidence for a novel endothelial
cell survival pathway,” The American Journal of Pathology,
vol. 154, no. 4, pp. 1171–1180, 1999.
[44] P. P. Sainaghi, L. Collimedaglia, F. Alciato et al., “Elevation of
Gas6 protein concentration in cerebrospinal fluid of patients
with chronic inflammatory demyelinating polyneuropathy
(CIDP),” Journal of the Neurological Sciences, vol. 269, no. 1-
2, pp. 138–142, 2008.
[45] P. P. Sainaghi, M. Bellan, F. Lombino et al., “Growth arrest
specific 6 concentration is increased in the cerebrospinal fluid
of patients with Alzheimer's disease,” Journal of Alzheimer's
Disease, vol. 55, no. 1, pp. 59–65, 2017.
[46] M. Bellan, G. Pogliani, C. Marconi et al., “Gas6 as a putative
noninvasive biomarker of hepatic fibrosis,” Biomarkers in
Medicine, vol. 10, no. 12, pp. 1241–1249, 2016.
[47] M. Bellan, P. P. Sainaghi, M. T. Minh et al., “Gas6 as a predic-
tor of esophageal varices in patients affected by hepatitis C
virus related-chronic liver disease,” Biomarkers in Medicine,
vol. 12, no. 1, pp. 27–34, 2018.
[48] P. P. Sainaghi, L. Collimedaglia, F. Alciato et al., “Growth arrest
specific gene 6 protein concentration in cerebrospinal fluid
correlates with relapse severity inmultiple sclerosis,”Mediators
of Inflammation, vol. 2013, Article ID 406483, 7 pages, 2013.
[49] C. Ekman, A. Jönsen, G. Sturfelt, A. A. Bengtsson, and
B. Dahlbäck, “Plasma concentrations of Gas6 and sAxl corre-
late with disease activity in systemic lupus erythematosus,”
Rheumatology, vol. 50, no. 6, pp. 1064–1069, 2011.
[50] H. Zhu, X. Sun, L. Zhu et al., “Different expression patterns
and clinical significance of mAxl and sAxl in systemic lupus
erythematosus,” Lupus, vol. 23, no. 7, pp. 624–634, 2014.
[51] S. Guermazi, M. Hamza, and K. Dellagi, “Protein S deficiency
and antibodies to protein S in patients with Behçet's disease,”
Thrombosis Research, vol. 86, no. 3, pp. 197–204, 1997.
[52] E. Aadland, O. R. Odegaard, A. Røseth, and K. Try, “Free pro-
tein S deficiency in patients with chronic inflammatory bowel
disease,” Scandinavian Journal of Gastroenterology, vol. 27,
no. 11, pp. 957–960, 1992.
[53] G. Mudduluru, P. Ceppi, R. Kumarswamy, G. V. Scagliotti,
M. Papotti, and H. Allgayer, “Regulation of Axl receptor tyro-
sine kinase expression by miR-34a and miR-199a/b in solid
cancer,” Oncogene, vol. 30, no. 25, pp. 2888–2899, 2011.
[54] P. Jiang, R. Liu, Y. Zheng et al., “MiR-34a inhibits
lipopolysaccharide-induced inflammatory response through
targeting Notch1 in murine macrophages,” Experimental Cell
Research, vol. 318, no. 10, pp. 1175–1184, 2012.
[55] M. Kurowska-Stolarska, S. Alivernini, E. G. Melchor et al.,
“Micro RNA-34a dependent regulation of AXL controls the
activation of dendritic cells in inflammatory arthritis,” Nature
Communications, vol. 8, article 15877, 2017.
[56] T. D. Camenisch, B. H. Koller, H. S. Earp, and G. K. Matsu-
shima, “A novel receptor tyrosine kinase, Mer, inhibits TNF-
alpha production and lipopolysaccharide-induced endotoxic
shock,” The Journal of Immunology, vol. 162, no. 6,
pp. 3498–3503, 1999.
[57] J. Wang, Y. Hu, W. W. Deng, and B. Sun, “Negative regulation
of Toll-like receptor signaling pathway,” Microbes and Infec-
tion, vol. 11, no. 3, pp. 321–327, 2009.
[58] T. Deng, Y. Zhang, Q. Chen, K. Yan, and D. Han, “Toll-like
receptor-mediated inhibition of Gas6 and ProS expression
8 Disease Markers
facilitates inflammatory cytokine production in mouse macro-
phages,” Immunology, vol. 135, no. 1, pp. 40–50, 2012.
[59] C. Q. Chu, M. Field, M. Feldmann, and R. N. Maini, “Localiza-
tion of tumor necrosis factor alpha in synovial tissues and at
the cartilage-pannus junction in patients with rheumatoid
arthritis,” Arthritis & Rheumatism, vol. 34, no. 9, pp. 1125–
1132, 1991.
[60] A. Kennedy, U. Fearon, D. J. Veale, and C. Godson, “Macro-
phages in synovial inflammation,” Front Immun Frontiers,
vol. 2, p. 52, 2011.
[61] M. Feldmann and R. N. Maini, “Anti-TNFα therapy of
rheumatoid arthritis: what have we learned?,” Annual Review
of Immunology, vol. 19, no. 1, pp. 163–196, 2001.
[62] M. Mircic and A. Kavanaugh, “The clinical efficacy of
tocilizumab in rheumatoid arthritis,” Drugs Today., vol. 45,
no. 3, pp. 189–197, 2009.
[63] U. S. Gaipl, L. E. Munoz, G. Grossmayer et al., “Clearance
deficiency and systemic lupus erythematosus (SLE),” Journal
of Autoimmunity, vol. 28, no. 2-3, pp. 114–121, 2007.
[64] I. Baumann, W. Kolowos, R. E. Voll et al., “Impaired uptake of
apoptotic cells into tingible body macrophages in germinal
centers of patients with systemic lupus erythematosus,” Arthri-
tis and Rheumatism, vol. 46, no. 1, pp. 191–201, 2002.
[65] E. D. Lew, J. Oh, P. G. Burrola et al., “Differential TAM
receptor-ligand-phospholipid interactions delimit differential
TAM bioactivities,” Elife, vol. 3, p. 87, 2014.
[66] R. S. Scott, E. J. McMahon, S. M. Pop et al., “Phagocytosis and
clearance of apoptotic cells is mediated by MER,” Nature,
vol. 411, no. 6834, pp. 207–211, 2001.
[67] B. Bartok and G. S. Firestein, “Fibroblast-like synoviocytes: key
effector cells in rheumatoid arthritis,” Immunological Reviews,
vol. 233, no. 1, pp. 233–255, 2010.
[68] E. A. Carrera-Silva, P. Y. Chan, L. Joannas et al., “T cell-
derived protein S engages TAM receptor signaling in dendritic
cells to control the magnitude of the immune response,”
Immunity, vol. 39, no. 1, pp. 160–170, 2013.
[69] K. Fischer, S. Voelkl, J. Berger, R. Andreesen, T. Pomorski, and
A. Mackensen, “Antigen recognition induces phosphatidylser-
ine exposure on the cell surface of human CD8+ T cells,” Blood,
vol. 108, no. 13, pp. 4094–4101, 2006.
[70] H. Kelchtermans, L. Geboes, T. Mitera, D. Huskens,
G. Leclercq, and P. Matthys, “Activated CD4+CD25+ regula-
tory T cells inhibit osteoclastogenesis and collagen-induced
arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 5,
pp. 744–750, 2009.
[71] P. L. Cohen and W.-H. Shao, “Gas6/TAM receptors in
systemic lupus erythematosus,” Disease Markers, vol. 2019,
Article ID 7838195, 9 pages, 2019.
[72] C. E. J. Waterborg, M. I. Koenders, P. L. E. M. van Lent, P. M.
van der Kraan, and F. A. J. van de Loo, “Tyro3/Axl/Mertk-defi-
cient mice develop bonemarrow edema which is an early path-
ological marker in rheumatoid arthritis,” PLoS One, vol. 13,
no. 10, article e0205902, 2018.
[73] A. Picchianti-Diamanti, C. Panebianco, S. Salemi et al.,
“Analysis of gut microbiota in rheumatoid arthritis patients:
disease-related dysbiosis and modifications induced by
etanercept,” International Journal of Molecular Sciences,
vol. 19, no. 10, article 2938, 2018.
[74] C. E. J. Waterborg, S. Beermann, M. G. A. Broeren et al.,
“Protective role of the MER tyrosine kinase via Efferocytosis
in rheumatoid arthritis models,” Frontiers in Immunology,
vol. 9, p. 742, 2018.
[75] C. E. J. Waterborg, M. G. A. Broeren, E. N. Blaney Davidson
et al., “The level of synovial AXL expression determines the
outcome of inflammatory arthritis, possibly depending on
the upstream role of TGF-β1,” Rheumatology, vol. 58, no. 3,
pp. 536–546, 2018.
[76] B. T. van den Brand, S. Abdollahi-Roodsaz, E. A. Vermeij et al.,
“Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase
agonists in collagen-induced arthritis,” Arthritis and Rheuma-
tism, vol. 65, no. 3, pp. 671–680, 2013.
[77] F. Ye, L. Han, Q. Lu et al., “Retinal self-antigen induces a
predominantly Th1 effector response in Axl and Mertk
double-knockout mice,” The Journal of Immunology,
vol. 187, no. 8, pp. 4178–4186, 2011.
[78] S. Culemann, A. Grüneboom, J. Á. Nicolás-Ávila et al.,
“Locally renewing resident synovial macrophages provide a
protective barrier for the joint,” Nature, vol. 572, no. 7771,
pp. 670–675, 2019.
[79] G. Ruiz-Heiland, Y. Zhao, A. Derer et al., “Deletion of the
receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia
and bone damage in arthritis,” Annals of the Rheumatic
Diseases, vol. 73, no. 4, pp. 771–779, 2014.
[80] L. Xu, F. Hu, H. Zhu et al., “Soluble TAM receptor tyrosine
kinases in rheumatoid arthritis: correlation with disease
activity and bone destruction,” Clinical and Experimental
Immunology, vol. 192, no. 1, pp. 95–103, 2018.
[81] Y. Degboé, B. Rauwel, M. Baron et al., “Polarization of
rheumatoid macrophages by TNF targeting through an IL-
10/STAT3 mechanism,” Frontiers in Immunology, vol. 10,
p. 3, 2019.
[82] F. Zhang, K. Wei, K. Slowikowski et al., “Defining inflamma-
tory cell states in rheumatoid arthritis joint synovial tissues
by integrating single-cell transcriptomics and mass cytome-
try,” Nature Immunology, vol. 20, no. 7, pp. 928–942, 2019.
[83] S. R. Finlay, S. Alivernini, A. Elmesmari et al., “OP0269 Activa-
tion of mertk+cd206+ subpopulation of human synovial
tissue-resident macrophages limits inflammatory response,”
Annals of the Rheumatic Diseases, vol. 77, Supplement 2,
pp. 183–183, 2018.
[84] J. Wu, C. Ekman, A. Jönsen et al., “Increased plasma levels of
the soluble Mer tyrosine kinase receptor in systemic lupus
erythematosus relate to disease activity and nephritis,” Arthri-
tis Research & Therapy, vol. 13, no. 2, article R62, 2011.
[85] M. Bhattacharjee, L. Balakrishnan, S. Renuse et al., “Synovial
fluid proteome in rheumatoid arthritis,” Clinical Proteomics,

















































































Submit your manuscripts at
www.hindawi.com
